This report was first published by Endpoints News. To see the original version, click here
It seems there’s room for two in the MASH market.
When Novo Nordisk’s blockbuster weight loss drug Wegovy won approval in August 2025 to treat the fatty liver disease, some investors thought it would put competitive pressure on Madrigal Pharmaceuticals’ liver-targeted therapy Rezdiffra, causing Madrigal’s stock to dip that day.
您已阅读15%（418字），剩余85%（2408字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。